Sarepta Woes Mount as Duchenne Gene Therapy Knocked Back in Europe

Sarepta falls after it fails to get EU approval

Elevidys, which is marketed by Roche outside the US, accounts for half of the company’s revenue....

Pharmalittle: We’re watching Europe moving to reject Elevidys, a FDA panel on SSRI risks, and more

Good morning dearest readers, this is Allison, filling in for Mr. Pharmalittle. I’m coming to you with a little bit of coffee envy — yesterday, one of the investors I follow on LinkedIn revealed that he was recently able to buy a La Marzocco espresso machine from a startup that was going out of business. These machines start at $5,000 and can cost up to $30,000. How much did he pay? Just $600. What’s the best deal you’ve gotten on a kitchen appl…

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 25, 2025-

Technicals Favor Further US Stock Gains

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could further jeopardize Sarepta’s financial future.

CHMP rejects Elevidys in latest setback for Sarepta

Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.